Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient.
Sims-McCallum
Rosalyn P
RP
Department of Pharmacy, Children's Hospital of Michigan, 3901 Beaubien, Detroit, MI 48201, USA. rsims@dmc.org
D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy*; D000077336:Caspofungin; D002648:Child; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D054714:Echinocandins; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D055666:Lipopeptides; D009503:Neutropenia / Q000150:complications*; D010455:Peptides / Q000627:therapeutic use*; D010456:Peptides, Cyclic; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D004338:Drug Combinations; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; D011743:Pyrimidines; D014230:Triazoles; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077336:Caspofungin; D065819:Voriconazole